[
  {
    "evidence_id": 3017,
    "gene": {
      "id": 5,
      "name": "BRAF",
      "entrez_id": 673
    },
    "variant": {
      "id": 12,
      "name": "V600E",
      "hgvs": "ENSP00000288602.7:p.Val600Glu",
      "chromosome": "7",
      "start": 140753336,
      "stop": 140753336,
      "reference_bases": "A",
      "variant_bases": "T",
      "variant_types": ["missense_variant"]
    },
    "disease": {
      "id": 15,
      "name": "Melanoma",
      "doid": "1909",
      "display_name": "Melanoma"
    },
    "drugs": [
      {"id": 22, "name": "Vemurafenib", "ncit_id": "C64768"},
      {"id": 23, "name": "Dabrafenib", "ncit_id": "C82386"}
    ],
    "evidence_type": "Predictive",
    "evidence_direction": "Supports",
    "evidence_level": "A",
    "clinical_significance": "Sensitivity/Response",
    "rating": 5,
    "status": "accepted",
    "source": {
      "id": 123,
      "citation": "Chapman PB et al., 2011, N Engl J Med",
      "pubmed_id": "21639808"
    },
    "description": "BRAF V600E mutations predict response to vemurafenib in metastatic melanoma with significant improvement in overall survival."
  },
  {
    "evidence_id": 4521,
    "gene": {
      "id": 19,
      "name": "EGFR",
      "entrez_id": 1956
    },
    "variant": {
      "id": 33,
      "name": "L858R",
      "hgvs": "ENSP00000275493.3:p.Leu858Arg",
      "chromosome": "7",
      "start": 55259515,
      "stop": 55259515,
      "reference_bases": "T",
      "variant_bases": "G",
      "variant_types": ["missense_variant"]
    },
    "disease": {
      "id": 30,
      "name": "Lung Non-small Cell Carcinoma",
      "doid": "3908",
      "display_name": "Non-Small Cell Lung Cancer"
    },
    "drugs": [
      {"id": 15, "name": "Erlotinib", "ncit_id": "C65530"},
      {"id": 16, "name": "Gefitinib", "ncit_id": "C1855"}
    ],
    "evidence_type": "Predictive",
    "evidence_direction": "Supports",
    "evidence_level": "A",
    "clinical_significance": "Sensitivity/Response",
    "rating": 5,
    "status": "accepted",
    "source": {
      "id": 456,
      "citation": "Mok TS et al., 2009, N Engl J Med",
      "pubmed_id": "19692680"
    },
    "description": "EGFR L858R mutations predict sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer."
  },
  {
    "evidence_id": 6789,
    "gene": {
      "id": 45,
      "name": "TP53",
      "entrez_id": 7157
    },
    "variant": {
      "id": 78,
      "name": "R175H",
      "hgvs": "ENSP00000269305.5:p.Arg175His",
      "chromosome": "17",
      "start": 7673803,
      "stop": 7673803,
      "reference_bases": "G",
      "variant_bases": "A",
      "variant_types": ["missense_variant"]
    },
    "disease": {
      "id": 50,
      "name": "Cancer",
      "doid": "162",
      "display_name": "Cancer"
    },
    "drugs": [],
    "evidence_type": "Prognostic",
    "evidence_direction": "Supports",
    "evidence_level": "B",
    "clinical_significance": "Poor Outcome",
    "rating": 4,
    "status": "accepted",
    "source": {
      "id": 789,
      "citation": "Olivier M et al., 2010, Hum Mutat",
      "pubmed_id": "19847789"
    },
    "description": "TP53 R175H is a hotspot mutation associated with loss of tumor suppressor function and poor prognosis across multiple cancer types."
  }
]
